Welcome to our dedicated page for Beyond Air SEC filings (Ticker: XAIR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Struggling to decode Beyond Air’s dense biotech disclosures? Clinical-stage filings can run hundreds of pages, packed with trial data, FDA risk factors, and nitric-oxide science that’s easy to miss. Our platform surfaces what matters—from LungFit™ revenue projections to cash runway assumptions—without forcing you to sift through every footnote.
Stock Titan’s AI reads every new document the moment it hits EDGAR. Get instant clarity on a Beyond Air quarterly earnings report 10-Q filing, line-item R&D expenses, or the exact wording of a Beyond Air 8-K material events explained notice. Need to follow management moves? Real-time alerts flag Beyond Air insider trading Form 4 transactions so you can monitor buying or selling before key clinical updates. Our AI-powered summaries translate technical language into plain English, turning “understanding Beyond Air SEC documents with AI” from wishful thinking into a daily workflow.
Every filing type is covered: the Beyond Air annual report 10-K simplified spells out regulatory pathways and market size estimates; Beyond Air proxy statement executive compensation reveals how bonuses hinge on trial milestones; and Beyond Air earnings report filing analysis highlights quarter-over-quarter cash burn. You’ll also find a full log of Beyond Air Form 4 insider transactions real-time and downloadable exhibits for deeper due diligence. Save hours, spot red flags early, and make confident calls on XAIR—all with AI guidance and continuously updated data.
Balyasny Asset Management and affiliated entities disclose beneficial ownership of 12,290,913 shares of Beyond Air common stock, representing approximately 9.99% of the outstanding class based on the issuer's reported share count. The reported position includes 8,956,504 shares issuable upon exercise of warrants, but a contractual 9.99% blocker prevents the Reporting Persons from exercising any warrants that would result in ownership above 9.99%.
The filing states each Reporting Person has sole voting and dispositive power over the 12,290,913 shares and identifies ADMF as the direct holder and an investment management client of BAM with rights to dividends and sale proceeds. Filers certify the securities were acquired in the ordinary course of business and not to influence control.
Beyond Air reported operational progress but faces a near-term funding gap. Revenue for the three months ended June 30, 2025 rose to $1.76 million from $0.68 million a year earlier, producing a $156,000 gross profit versus a prior gross loss. Operating losses narrowed to $7.62 million and net loss improved to $8.08 million from $13.06 million, reflecting lower R&D and SG&A spend. The company held $6.63 million of cash, marketable securities and restricted cash at period end but used $4.53 million in operating cash flow during the quarter. Management disclosed substantial doubt about meeting obligations with current resources and stated additional funding will be required within one year. Financing actions during the quarter included $2.4 million net ATM proceeds and a $2.0 million related-party advance; long-term debt outstanding under the Loan Agreement remains $11.5 million (facility terms include a 15% annual interest structure). The company has FDA PMA for LungFit PH and CE mark approval for additional indications, and effected a one-for-twenty reverse stock split with retroactive presentation of prior-period per-share amounts.
Beyond Air held a Special Meeting of stockholders on June 20, 2025, where shareholders approved a significant Reverse Stock Split proposal. Out of 86,369,869 outstanding shares, 48,476,717 shares were represented at the meeting, constituting a quorum.
Key details of the approved proposal:
- Authorizes the Board to implement a reverse stock split within one year
- Split ratio range between 1-for-10 and 1-for-50
- Voting results: 41,924,612 votes in favor, 6,382,862 against, 169,243 abstentions
This strategic move gives the Board flexibility to consolidate shares, potentially improving the company's market position and stock price structure. The strong shareholder support (86.5% of votes cast in favor) demonstrates confidence in the Board's management strategy.
Beyond Air (NASDAQ: XAIR) filed its Form 10-K Annual Report on June 29, 2025. The excerpt supplied consists almost entirely of XBRL taxonomy tags and entity identifiers, with no accompanying financial statements, narrative sections, risk factors, legal proceedings, or management discussion. Because the critical quantitative and qualitative disclosures normally included in a 10-K are absent from the provided content, no material information relevant to investors can be summarized from this excerpt.
Beyond Air (NASDAQ: XAIR) reported several significant developments in this 8-K filing:
Key Events:
- Released financial results for fiscal quarter and year ended March 31, 2025 (detailed results not provided in filing)
- Appointed Robert Goodman to Board of Directors on June 16, 2025 - Qualified as independent director under Nasdaq standards - Notable experience with BioTelemetry, Philips Healthcare, Cardiocore, Thermo Fisher Scientific, and Pfizer
- Submitted PMA supplement application to FDA for LungFit PH II, their next-generation therapeutic nitric oxide generator
The company filed two press releases as exhibits (99.1 and 99.2) detailing the financial results and FDA submission respectively. The appointment of Goodman strengthens the board with extensive healthcare industry expertise, while the FDA submission represents a significant regulatory milestone for their therapeutic device development program.
FAQ
What is the current stock price of Beyond Air (XAIR)?
What is the market cap of Beyond Air (XAIR)?
